Hainan Haiyao Past Earnings Performance
Past criteria checks 0/6
Hainan Haiyao's earnings have been declining at an average annual rate of -2.2%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 11.7% per year.
Key information
-2.2%
Earnings growth rate
-2.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -11.7% |
| Return on equity | -16.1% |
| Net Margin | -28.4% |
| Last Earnings Update | 30 Jun 2024 |
Revenue & Expenses Breakdown
How Hainan Haiyao makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1,112 | -316 | 400 | 59 |
| 31 Mar 24 | 1,347 | -127 | 451 | 63 |
| 31 Dec 23 | 1,479 | -106 | 494 | 55 |
| 30 Sep 23 | 1,557 | 53 | 691 | 49 |
| 31 Mar 23 | 1,720 | 33 | 775 | 50 |
| 01 Jan 23 | 1,779 | 11 | 825 | 49 |
| 30 Sep 22 | 2,034 | -1,126 | 1,107 | 187 |
| 30 Jun 22 | 2,094 | -1,197 | 1,187 | 192 |
| 31 Mar 22 | 2,067 | -1,422 | 1,297 | 197 |
| 01 Jan 22 | 2,059 | -1,555 | 1,304 | 197 |
| 30 Sep 21 | 2,038 | -1,097 | 1,444 | 132 |
| 30 Jun 21 | 2,157 | -1,011 | 1,480 | 131 |
| 31 Mar 21 | 2,243 | -630 | 1,404 | 129 |
| 31 Dec 20 | 2,200 | -580 | 1,456 | 126 |
| 30 Sep 20 | 2,173 | -263 | 1,439 | 124 |
| 30 Jun 20 | 2,111 | -187 | 1,402 | 107 |
| 31 Mar 20 | 2,192 | -334 | 1,557 | 102 |
| 31 Dec 19 | 2,445 | -159 | 1,514 | 92 |
| 30 Sep 19 | 2,355 | 14 | 1,081 | 15 |
| 30 Jun 19 | 2,727 | 51 | 1,042 | 18 |
| 31 Mar 19 | 2,570 | 121 | 1,038 | 19 |
| 31 Dec 18 | 2,472 | 120 | 1,026 | 19 |
| 30 Sep 18 | 2,616 | 140 | 1,114 | 45 |
| 30 Jun 18 | 2,214 | 123 | 1,000 | 43 |
| 31 Mar 18 | 2,075 | 93 | 749 | 33 |
| 31 Dec 17 | 1,825 | 87 | 661 | 31 |
| 30 Sep 17 | 1,753 | 172 | 602 | 4 |
| 30 Jun 17 | 1,511 | 164 | 572 | 0 |
| 31 Mar 17 | 1,541 | 172 | 577 | 0 |
| 31 Dec 16 | 1,509 | 165 | 554 | 0 |
| 30 Sep 16 | 1,457 | 132 | 424 | 0 |
| 30 Jun 16 | 1,594 | 196 | 423 | 0 |
| 31 Mar 16 | 1,649 | 197 | 428 | 0 |
| 31 Dec 15 | 1,644 | 195 | 423 | 0 |
| 30 Sep 15 | 1,484 | 226 | 359 | 0 |
| 30 Jun 15 | 1,428 | 182 | 363 | 0 |
| 31 Mar 15 | 1,371 | 178 | 352 | 0 |
| 31 Dec 14 | 1,343 | 163 | 331 | 0 |
| 30 Sep 14 | 1,264 | 178 | 322 | 0 |
| 30 Jun 14 | 1,185 | 129 | 317 | 0 |
| 31 Mar 14 | 1,018 | 96 | 315 | 0 |
| 31 Dec 13 | 1,018 | 94 | 308 | 0 |
| 30 Sep 13 | 1,119 | 71 | 329 | 0 |
Quality Earnings: 000566 is currently unprofitable.
Growing Profit Margin: 000566 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 000566 is unprofitable, and losses have increased over the past 5 years at a rate of 2.2% per year.
Accelerating Growth: Unable to compare 000566's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 000566 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (0.4%).
Return on Equity
High ROE: 000566 has a negative Return on Equity (-16.09%), as it is currently unprofitable.